Scleroderma Drug In Development PDF Print E-mail
Friday, 16 October 2009 10:57
According to The Commercial Appeal, arGentis Pharmaceutical has partnered with Shattuck Hammond Partners, the health care investment arm of Morgan Keegan and Co. Inc., to jump-start a capital campaign to raise $12 million to $15 million. ArGentis shelved the campaign last year when the economy soured.

The money will help continue a three-year effort by arGentis to shepherd a treatment for Scleroderma, an autoimmune disease that affects blood vessels and connective tissue. Ted Townsend, the company's vice president of business development, said the treatment could be on the market as early as 2013.

The company has just finished reviewing the treatment's previous clinical trial. The next trial will be the drug's last before it heads to the Food and Drug Administration for market approval. To help that process along, arGentis has assembled a "dream team" to serve on its scientific advisory board.

For example, new board member Maureen D. Mayes wrote "The Scleroderma Book" in 1999. University of California Los Angeles professor Daniel Furst, Georgetown School of Medicine professor Virginia D. Steen and UCLA biostatistics professor Weng Kee Wong also joined the arGentis scientific advisory board.

"These physicians understand this disease process better than anyone in the world," said Townsend. "Their participation in the trial shows the validity of our therapy and will hopefully reinforce our credibility to regulatory authorities."

However, Charles Spaulding, vice president of communications with the Scleroderma Research Foundation, said the disease largely flies under national research radar.

"There's not enough researchers looking at the disease and not enough money being spent on Scleroderma research," Spaulding said.

ArGentis' Scleroderma treatment received "orphan status" in the United States and in the European Union. The designation gives the company market exclusivity for seven years here and 10 years in Europe.

Townsend said the treatment could be a $1 billion annual opportunity in the U.S. and Europe.

The company also has license agreements in hand for about 50 markets globally.

To view the full article, click here.
 
More articles :

» Air Pollution Linked to Autoimmune Diseases

Many people with environmental illnesses have an assortment of autoimmune diseases which scientists are linking to air pollution.Though genetic factors have been found for autoimmune diseases, this knowledge has not helped to prevent them. In fact,...

» Dr. Dinesh Khanna Named, "Doctor Of The Year"

The Scleroderma Foundation named Dinesh Khanna, M.D., M.Sc., its 2011 Doctor of the Year during this year's National Patient Education Conference held last month in San Francisco. The award recognizes a skilled physician or researcher for his or her...

» Could The Drug Gleevec Be The First Possible Treatment For Scleroderma?

Investigators have identified a drug that is currently approved to treat certain types of cancer, , that could provide the first treatment for . The news will be presented at the annual meeting of the on October 18 in Philadelphia. "There has never...

» Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152

Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.  Completion of this study positions Amira to initiate a Phase 2a study in...

» A Brief Overview Of Rheumatoid Arthritis

The term arthritis refers to pain, swelling and stiffness of joints. However, joint pain is not a disease but a symptom. It is one of the ways the body tells you that something is wrong. With almost nine million people suffering from Rheumatoid...

» Pain Common in Systemic Sclerosis

Pain is common and can be severe in patients with systemic sclerosis, a cross-sectional analysis found.Among patients enrolled in the multicenter Canadian Scleroderma Research Group Registry, 83% experienced pain, more than one-third of them...